{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2023"],"data_sharing_plan":["IPD Sharing (as of April 2023): No"],"condition":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"disease":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2742027"],"location":["Australia"],"study_start_month":["4"],"keyword":["Irinotecan","Pembrolizumab"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer","description":"The study is a 2-part study of AUM001 alone on in combination with Pembrolizumab/Irinotecan in patients with CRC.","dates":{"creation":"2023-04-15"},"accession":"2742027","cross_references":{"ClinicalTrials___gov":["NCT05462236"]}}